Skip to main content
. Author manuscript; available in PMC: 2018 Feb 2.
Published in final edited form as: Exp Eye Res. 2016 Dec 15;155:64–74. doi: 10.1016/j.exer.2016.12.006

Figure 2. Serum from subjects with AMD reacts specifically with CD5L/AIM and exhibits also elevated circulating CD5L/AIM levels.

Figure 2

Circulating AAbs from a selection of AMD-affected study participants (n=18) specifically reacted with recombinant CD5L/AIM protein in a direct enzyme-linked immunosorbence assay (ELISA) over unaffected subjects (CTRL, n=15). The individual reactivities are shown as a scatterplot in Panel A. The average reactivity ± 1SD is also shown next to the scatterplots. The difference in anti-CD5L/AIM AAbs was highly significant (p=0.000007). An ELISA autoreactivity ≥0.4 against CD5L/AIM was associated with 18-fold higher likelihood of being from an AMD sample. The serum levels of free circulating CD5L/AIM measured by Western blots (WB) were also elevated in the serum of these AMD participants compared to the unaffected controls. Representative WB examples are illustrated in Panel B [red bands: transferrin (control); green bands: CD5L/AIM] and the individual reactivities are shown as a scatterplot in Panel C. The average reactivity ± 1SD is also shown next to the scatterplots. The difference was significant (p=0.0052). A linear correlation analysis between the AAb levels as detected by ELISA and the serum CD5L/AIM levels as measured by WB is plotted in Panel D, showing a weak trend towards an inverse correlation for both data subsets (AMD and control sera).